NCT06909643Completed
Development and Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
This study is a multi-center observational study without interventions, including the construction of an AI predictive model, with retrospective and prospective testing. The study participants are bladder cancer patients who have undergone imaging examinations, been pathologically diagnosed, and received neoadjuvant treatment, with complete clinical and pathological data. The study plans to enroll 130 patients from our center, collecting corresponding imaging images, and gathering clinical and genomic data to build and internally validate a multimodal AI model. The model's generalization and robustness will be tested to explore the association between multimodal data and the efficacy of neoadjuvant treatment for bladder cancer. The aim is to assist clinicians in predicting and evaluating the efficacy of neoadjuvant treatment for bladder cancer, with the goal of improving patient diagnosis, treatment outcomes, and prognosis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 469 (actual)
- First submitted
- 19 Mar 2025
- Start date
- Jan 2022
- Primary completion date
- Dec 2025
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Diseases
- Bladder cancer, Childhood cancers
- NCT number
- NCT06909643
What you commit to
- Study type: Observational
- Participants enrolled: 469
- From Jan 2022 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received local treatments (such as interventional embolization) or systemic treatments (such as radiotherapy, chemotherapy, immunotherapy, or targeted therapy).
Other
- Patients who have not undergone standard bladder imaging examinations or have missing imaging or pathological data.
- Poor quality of imaging or pathological images.
Who the study is looking for
- Bladder occupying lesions, with histopathological confirmation of bladder cancer after resection.
- Planned neoadjuvant therapy and radical cystectomy.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat Sen Memorial Hospital of Sun Yat sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.